Protective Effects of Huo Xiang Zheng Qi Liquid on Clostridioides difficile Infection on C57BL/6 Mice.

Autor:	Chen M; Department of Clinical Microbiology, University Hospital of Southern Denmark, 6200 Aabenraa, Denmark.; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark., Zhai L; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark., Schønning K; Department of Clinical Microbiology, University Hospital of Copenhagen, Hvidovre, 2650 Hvidovre, Denmark., Alpízar-Alpízar W; The Finsen Laboratory, The Finsen Center, Copenhagen University Hospital, 2200 Copenhagen, Denmark., Larum O; The Finsen Laboratory, The Finsen Center, Copenhagen University Hospital, 2200 Copenhagen, Denmark., Andersen LP; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark., Holck S; Department of Pathology, University Hospital of Copenhagen, Hvidovre, 2650 Hvidovre, Denmark., Friis-Møller A; Department of Clinical Microbiology, University Hospital of Copenhagen, Hvidovre, 2650 Hvidovre, Denmark.
Jazyk:	angličtina
Zdroj:	Microorganisms [Microorganisms] 2024 Aug 06; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 06.
DOI:	10.3390/microorganisms12081602
Abstrakt:	Background: Clostridioides difficile -associated disease (CDAD) is a major healthcare-associated infection. New treatment options for CDAD are needed. A traditional Chinese medicinal formula, Huo Xiang Zheng Qi (HXZQ), was chosen to test against CDAD in a mouse model. Methods: C57BL/6 mice were challenged with C difficile (ATCC 43255) orally; then received saline; vancomycin 25 mg/kg; or HXZQ in two different concentrations twice daily for 5 days. The animals' body weight; clinical signs; and survival rates were registered daily. Fecal pellets from each animal were taken for PCR analysis as a control of infection. Results: 50% of the mice receiving saline died; 85.7% of the mice receiving vancomycin survived; 75% of the mice receiving HXZQ survived; and 87.5% of the mice receiving a 1:1 saline dilution of HXZQ survived. The HXZQ-treated groups were C. difficile PCR positive with loads less than that of the untreated mice. The weight loss in the vancomycin plus HXZQ 1:1 treated group; the vancomycin-treated group; and the untreated group were 3.08%, 4.06%, and 9.62%, respectively. Conclusions: our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu